PARUCH, Kamil, Benoit Jean-Pierre CARBAIN, Štěpán HAVEL, Jiří DAMBORSKÝ, Jan BREZOVSKÝ, Lukáš DANIEL, Alexandra SISÁKOVÁ, Fedor NIKULENKOV and Lumír KREJČÍ. Substituted aminothiazoles as inhibitors of nucleases. 2023.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Substituted aminothiazoles as inhibitors of nucleases
Name (in English) Substituted aminothiazoles as inhibitors of nucleases
Authors PARUCH, Kamil (203 Czech Republic, belonging to the institution), Benoit Jean-Pierre CARBAIN (250 France, belonging to the institution), Štěpán HAVEL (203 Czech Republic, belonging to the institution), Jiří DAMBORSKÝ (203 Czech Republic, belonging to the institution), Jan BREZOVSKÝ (203 Czech Republic, belonging to the institution), Lukáš DANIEL (203 Czech Republic, belonging to the institution), Alexandra SISÁKOVÁ (703 Slovakia, belonging to the institution), Fedor NIKULENKOV (203 Czech Republic, belonging to the institution) and Lumír KREJČÍ (203 Czech Republic, belonging to the institution).
Edition Number: IL277866, Publisher: Israel Patent Office, Place of publication: Jerusalem, Owner's name: Masarykova univerzita, 2023.
Other information
Original language Yiddish
Type of outcome Patent
Field of Study 30107 Medicinal chemistry
Country of publisher Israel
Confidentiality degree is not subject to a state or trade secret
WWW Israel Patent Office URL
RIV identification code RIV/00216224:14310/23:00132705
Organization unit Faculty of Science
Keywords in English DNA; propanamide; nuclease
Tags rivok
Tags International impact
Changed by Changed by: Mgr. Marie Šípková, DiS., učo 437722. Changed: 6/8/2024 10:37.
Abstract
Compounds represented by the structural formula (1) R1, R2, R3, R4, R5, R6 are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.
Abstract (in English)
Compounds represented by the structural formula (1) R1, R2, R3, R4, R5, R6 are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.
PrintDisplayed: 6/10/2024 14:18